

for **HEMLIBRA**[®]
(emicizumab-kxwh)

SAMPLE CODING

Hemophilia A

TYPE	CODE	DESCRIPTION		
Diagnosis: ICD-10-CM	D66	Hereditary factor VIII deficiency: hemophilia A		
Drug: HCPCS	J7170	Injection, emicizumab-kxwh, 0.5 mg billable unit 1 mg=2 billable units		
HCPCS: Modifier* Note: As of January 1, 2024, CMS requires the use of the JZ modifier for HEMLIBRA to indicate there were no units of a drug discarded.	JZ	Zero drug amount discarded/not administered to any patient		
Drug: NDC	11-Digit	Package Size	Milligrams	Billable Units
	50242-0927-01	12 mg/0.4 mL (30 mg/mL)	12	24
	50242-0920-01	30 mg/1 mL (30 mg/mL)	30	60
	50242-0921-01	60 mg/0.4 mL (150 mg/mL)	60	120
	50242-0922-01	105 mg/0.7 mL (150 mg/mL)	105	210
	50242-0923-01	150 mg/1 mL (150 mg/mL)	150	300
	50242-0930-01	300 mg/2 mL (150 mg/mL)	300	600
Administration procedures: CPT	96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular		

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

*The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

You may only need the ICD-10-CM and NDC when the specialty pharmacy ships emicizumab-kxwh directly to the patient's home.

HEMLIBRA[®] is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

Please see the HEMLIBRA full [Prescribing Information](#) for Important Safety Information, including **Boxed WARNING**.